Cost-Effectiveness of Inhaled Nitric Oxide in the Treatment of Neonatal Respiratory Failure in the US

Pediatrics

Volumn 112, Issue 6 I, 2003, Pages 1422-1423

  Field, David ^a,b   Normand, Charles ^c   Elbourne, Diana ^c  

^a LEICESTER ROYAL INFIRMARY   (United Kingdom)

^b UNIVERSITY OF LEICESTER   (United Kingdom)

^c LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

NITRIC OXIDE;

COST EFFECTIVENESS ANALYSIS; EXTRACORPOREAL OXYGENATION; HEALTH CARE COST; HUMAN; NEONATAL RESPIRATORY DISTRESS SYNDROME; NEWBORN; NOTE; PRIORITY JOURNAL; RESPIRATORY DISTRESS; RESPIRATORY FAILURE; UNITED STATES;

ANOXIA; COST-BENEFIT ANALYSIS; EXTRACORPOREAL MEMBRANE OXYGENATION; HUMANS; INFANT, NEWBORN; NITRIC OXIDE; RESPIRATORY INSUFFICIENCY; VASODILATOR AGENTS;

EID: 0346850816     PISSN: 00314005     EISSN: None     Source Type: Journal    
DOI: 10.1542/peds.112.6.1422     Document Type: Note

References (3)

1. Angus DC, Clermont G, Watson RS, Linde-Zwirble WT, Clark RH, Roberts MS. Cost-effectiveness of inhaled nitric oxide in the treatment of neonatal respiratory failure in the united states. Pediatrics. 2003;112: 1351-1360
2. UK Collaborative ECMO Group. The collaborative UK ECMO trial: follow-up to 1 year of age. Pediatrics. 1998;101(4). Available at: http:// www.pediatrics.org/cgi/content/full/101/4/e1
3. Bennett CC, Johnson A, Field DJ, Elbourne D. UK collaborative randomised trial of neonatal extracorporeal membrane oxygenation: follow-up to age 4 years. Lancet. 2001;357:1094-1096.